Constellation Pharmaceuticals Inc

+0.02 (+0.06%)
Debt Financing / Related, Mergers / Acquisitions

Morphosys To Buy Constellation Pharmaceuticals

Published: 06/02/2021 11:32 GMT
Constellation Pharmaceuticals Inc (CNST) - Morphosys Ag to Acquire Constellation Pharmaceuticals and Enter Into Strategic Funding Partnership With Royalty Pharma.
Deal to Close in Q3 of 2021.
Also Announced That It Has Entered Into a Long-term Strategic Funding Partnership With Royalty Pharma Plc.
Royalty Pharma Will Make a $1.425 Billion Upfront Payment to Morphosys, Supporting Its Growth Strategy.
Will Acquire Constellation for $34.00 per Share in Cash, Which Represents a Total Equity Value of $1.7 Billion.
Plans to Pay All-cash Consideration for Transaction.
Royalty Pharma Will Have Rights to Receive 100% of Morphosys' Royalties on Net Sales of Tremfya.
Royalty Pharma Will Also Have Rights to Receive 80% of Future Royalties and 100% of Future Milestone Payments on Otilimab, 60% of Future Royalties on Gantenerumab, and 3% on Future Net Sales of Constellation's Clinical Stage Assets (pelabresib and Cpi-0209).